Intercept Pharms Inc Drug Patent Portfolio

Intercept Pharms Inc owns 1 orange book drug protected by 10 US patents Given below is the list of Intercept Pharms Inc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10052337 Compositions of obeticholic acid and methods of use 26 Apr, 2036
Active
US10751349 Compositions of obeticholic acid and methods of use 26 Apr, 2036
Active
US10758549 Compositions of obeticholic acid and methods of use 26 Apr, 2036
Active
US10047117 Preparation and uses of obeticholic acid 06 Sep, 2033
Active
US10174073 Preparation and uses of obeticholic acid 17 Jun, 2033
Active
US9238673 Preparation and uses of obeticholic acid 17 Jun, 2033
Active
USRE48286 Steroids as agonists for FXR 21 Feb, 2027
Active
US7138390 Steroids as agonists for FXR 16 Nov, 2022 Expired
US8058267 Steroids as agonists for FXR 21 Feb, 2022 Expired
US8377916 Steroids as agonists for FXR 21 Feb, 2022 Expired


Given below is the list of recent legal activities going on the following drug patents of Intercept Pharms Inc.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 01 Mar, 2024 US10758549
Payment of Maintenance Fee, 4th Year, Large Entity 26 Feb, 2024 US10751349
Expire Patent 18 Dec, 2023 US8058267
Payment of Maintenance Fee, 8th Year, Large Entity 19 Jul, 2023 US9238673
Maintenance Fee Reminder Mailed 03 Jul, 2023 US8058267
Payment of Maintenance Fee, 4th Year, Large Entity 08 Jul, 2022 US10174073
Payment of Maintenance Fee, 4th Year, Large Entity 21 Feb, 2022 US10052337
Payment of Maintenance Fee, 4th Year, Large Entity 14 Feb, 2022 US10047117
Mail-Petition Decision - Granted 06 Nov, 2020 US7138390
Petition Decision - Granted 05 Nov, 2020 US7138390
Petition Entered 28 Oct, 2020 US7138390
Recordation of Patent Grant Mailed 01 Sep, 2020 US10758549
Patent Issue Date Used in PTA Calculation 01 Sep, 2020 US10758549
Patent Issue Date Used in PTA Calculation 25 Aug, 2020 US10751349
Recordation of Patent Grant Mailed 25 Aug, 2020 US10751349


Intercept Pharms Inc's Family Patents

Intercept Pharms Inc drugs have patent protection in a total of 38 countries. It's US patent count contributes only to 23.2% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Intercept Pharms Inc Drug List

Given below is the complete list of Intercept Pharms Inc's drugs and the patents protecting them.


1. Ocaliva

Ocaliva is protected by 10 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10052337 Compositions of obeticholic acid and methods of use 26 Apr, 2036
(11 years from now)
Active
US10751349 Compositions of obeticholic acid and methods of use 26 Apr, 2036
(11 years from now)
Active
US10758549 Compositions of obeticholic acid and methods of use 26 Apr, 2036
(11 years from now)
Active
US10047117 Preparation and uses of obeticholic acid 06 Sep, 2033
(8 years from now)
Active
US10174073 Preparation and uses of obeticholic acid 17 Jun, 2033
(8 years from now)
Active
US9238673 Preparation and uses of obeticholic acid 17 Jun, 2033
(8 years from now)
Active
USRE48286 Steroids as agonists for FXR 21 Feb, 2027
(2 years from now)
Active
US7138390 Steroids as agonists for FXR 16 Nov, 2022
(1 year, 10 months ago)
Expired
US8058267 Steroids as agonists for FXR 21 Feb, 2022
(2 years ago)
Expired
US8377916 Steroids as agonists for FXR 21 Feb, 2022
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ocaliva's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List